<DOC>
	<DOCNO>NCT02599792</DOCNO>
	<brief_summary>Two-part study assess CTP-656 dose solid oral dosage form versus Kalydeco multiple-ascending dose CTP-656 dose 7 day .</brief_summary>
	<brief_title>Healthy Volunteer Solid Oral Dose Multiple Ascending Dose Evaluation CTP-656</brief_title>
	<detailed_description>This two-part study ass healthy male female subject solid oral dose formulation CTP-656 vs. Kalydeco® safety , tolerability pharmacokinetic profile escalate CTP-656 solid oral dos follow 7 day dose . In Part B , three dos CTP-656 range 75 mg 300 mg per day study .</detailed_description>
	<criteria>Healthy adult 18 50 year age , inclusive Body weight ≥ 50 kg BMI within range 18 30 kg/m2 , inclusive , screen History clinically significant central nervous system ( eg , seizure ) , cardiac , pulmonary , metabolic , renal ( include nephrolithiasis ) , hepatic , include history Gilbert 's syndrome gastrointestinal ( GI ) condition PR interval ≥ 220 msec QRS duration ≥ 120 msec QTcF interval &gt; 450 msec obtain screen visit prior first dose study drug Liver function test great upper limit normal . Positive blood screen human immunodeficiency virus ( HIV antibody ) , hepatitis B virus surface antigen , hepatitis C virus antibody screen Urinalysis positive great trace blood , protein glucose A positive screen alcohol , drug abuse , tobacco use . Inability comply food beverage restriction study participation . Donation blood collection acute loss blood prior screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Safety Pharmacokinetics</keyword>
</DOC>